Founded in 2005, C3 Jian, Inc ("C3") is a clinical-stage biotechnology company based in Los Angeles, California whose technologies were pioneered in the laboratories of Dr. Wenyuan Shi at UCLA. We are developing several novel product platforms to diagnose and treat infectious disease, disorders of mineralization, and hair loss. Our lead anti-infectives are targeted against bacterial and fungal infections, specifically those occurring at mucosal surfaces where clear benefits are associated with retaining beneficial bacteria that conventional antibiotics would destroy.

Mission

Our mission is to provide targeted solutions, including diagnostics and therapeutics, which will offer more selective, efficacious and safer treatment modalities for infectious diseases and disorders of mineralization.

History

A brief overview of the history of C3 can be found below. C3 has worked closely with UCLA on development of its novel technologies.

• 2004 UCLA researchers successfully develop first prototype Specifically-Targeted
  Antimicrobial Peptide, or STAMP.



• 2005 UCLA researchers develop lead biomineralization modulating peptide
  
  
  
• 2006 UCLA researchers develop lead STAMP against S. mutans
  C3 Jian, Inc is established to develop and commercialize UCLA inventions



• 2007 C3 Inglewood R&D laboratories are opened
  C3 advances R&D on STAMPs and biomineralization modulating peptides
  
  
  
• 2008 C3 advances R&D on STAMPs and biomineralization modulating peptides
  Intelliherb LLC subsidiary is established
  C3 diagnostic products R&D is commenced
  Lead compound/formulations for hair growth are developed



• 2009 C3 Inglewood Peptide Synthesis Center opened. Prototype peptide-based
  S. mutans diagnostic constructed.
Anti-Candida albicans STAMP project initiated.